Stephen Johnson
About Stephen Johnson
Stephen Johnson is the Executive Director of Molecular Structure and Design at Bristol Myers Squibb and a Member of the Board of Trustees at Boheme Opera NJ, residing in West Windsor, New Jersey.
Current Role at Bristol Myers Squibb
Stephen Johnson currently holds the position of Executive Director, Molecular Structure and Design at Bristol Myers Squibb in Trenton, New Jersey. He started this role on April 1, 2021. In this capacity, Stephen leads the Molecular Structure & Design team, focusing on quality science and targeted innovation. He is responsible for driving the strategic direction and execution of molecular structure initiatives within the company.
Previous Positions at Bristol Myers Squibb
Stephen Johnson has an extensive career history with Bristol Myers Squibb. Before his current role, he served as Senior Director, Molecular Structure and Design from 2020 to 2021. From 2018 to 2020, he was Director, Computer-Assisted Drug Design based in Princeton, NJ. Prior to that, he worked as Senior Principal Scientist, CADD, for 17 years, from 2001 to 2018. These roles allowed him to develop a strong track record of pipeline impact in the scientific field.
Role at Boheme Opera NJ
In addition to his work at Bristol Myers Squibb, Stephen Johnson is currently a Member of the Board of Trustees at Boheme Opera NJ located in Trenton, New Jersey. His involvement in the board demonstrates his commitment to contributing to the community and engaging in local cultural initiatives.
Education and Academic Background
Stephen Johnson studied Chemistry at Penn State University, earning his PhD from 1994 to 1999. He previously earned his B.S. in Chemistry from the University of Delaware, spanning from 1990 to 1994. His academic background provided a strong foundation for his subsequent career in molecular structure and drug design.
Early Career at GlaxoSmithKline
Before joining Bristol Myers Squibb, Stephen Johnson worked at GlaxoSmithKline as an Investigator in Cheminformatics from 1999 to 2001. This role marked the onset of his professional journey in the field of computer-aided drug design and molecular science.